After 2024, which saw a steady recovery by the life sciences industry, it looks like 2025 is set to be a year of change and ...
StudyFinds on MSN14h
Personalized vaccines halt kidney cancer after encouraging phase 1 trialGroundbreaking personalized kidney cancer vaccines show promise in early clinical trials, triggering strong immune responses ...
The platform enables direct, unbiased genome-wide identification and quantification of the exact position of double strand DNA breaks in edited cells.
CHATHAM, N.J. - Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP), a clinical-stage biotech company with a market capitalization of $28 million, announced today positive outcomes from its Phase 1 ...
Will the Senate GOP confirm controversial picks like Tulsi Gabbard and RFK Jr.? Here’s the hearings schedule and list of ...
FDA’s Rare Disease Innovation Hub Releases Strategic Agenda: Implications for Stakeholders in 2025
In honor of Rare Disease Day on February 28, 2025, we will publish a series of posts throughout the month on As Prescribed ...
Following the president’s recent executive order dismantling diversity, equity, and inclusion policies, the main page for the ...
A clinical trial comparing a one-page medication handout proposed by the U.S. Food and Drug Administration (FDA) with an ...
The FDA approved Datroway to treat metastatic or unresectable HR+/HER2- breast cancer in people who have tried standard chemo ...
Neuren Pharmaceuticals (ASX: NEU) has been granted the chance to talk to the U.S. Food and Drug Administration (FDA) about some of the positive indicators that may be expected from its upcoming Phase ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback